GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,284.00p
   
  • Change Today:
      9.00p
  • 52 Week High: 1,812.50
  • 52 Week Low: 1,264.00
  • Currency: UK Pounds
  • Shares Issued: 4,120.05m
  • Volume: 4,023,049
  • Market Cap: £52,902m
  • RiskGrade: 129
  • Beta: 0.06

Financial Analysis

Select chart: EPS | Dividend | Revenue

Key Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 34,099.00 6,968.00 115.90p 14.5 n/a -6% 80.00p 4.8%
31-Dec-21 24,696.00 3,599.00 90.56p 22.2 n/a -22% 80.00p 4.0%
31-Dec-22 29,324.00 5,628.00 139.70p 10.3 0.2 +54% 44.00p 3.1%
31-Dec-23 30,328.00 6,064.00 155.10p 9.4 0.9 +11% 58.00p 4.0%
31-Dec-24 31,376.00 3,477.00 159.30p 8.5 2.8 +3% 61.00p 4.5%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-25 32,875.30 9,284.60 168.90p 7.5 1.2 +6% 64.85p 0.0%
31-Dec-26 34,536.20 10,159.62 186.51p 6.8 0.7 +10% 69.45p 0.0%
31-Dec-27 35,929.88 10,757.30 198.93p 6.4 1.0 +7% 73.26p 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

Price / Earnings Data

5 Yr High 5 Yr Low 5 Yr Avg Curr / Avg
Latest 14.47 8.45 12.95 0.62

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

GSK Market Data

Currency UK Pounds
Share Price 1,284.00p
Change Today 9.00p
% Change 0.71 %
52 Week High 1,812.50
52 Week Low 1,264.00
Volume 4,023,049
Shares Issued 4,120.05m
Market Cap £52,902m
Beta 0.06
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
26.38% below the market average26.38% below the market average26.38% below the market average26.38% below the market average26.38% below the market average
91.49% above the sector average91.49% above the sector average91.49% above the sector average91.49% above the sector average91.49% above the sector average
Price Trend
30.76% below the market average30.76% below the market average30.76% below the market average30.76% below the market average30.76% below the market average
25.00% above the sector average25.00% above the sector average25.00% above the sector average25.00% above the sector average25.00% above the sector average
Income
75.24% above the market average75.24% above the market average75.24% above the market average75.24% above the market average75.24% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
46.11% below the market average46.11% below the market average46.11% below the market average46.11% below the market average46.11% below the market average
35.48% below the sector average35.48% below the sector average35.48% below the sector average35.48% below the sector average35.48% below the sector average

What The Brokers Say

Strong Buy 4
Buy 3
Neutral 15
Sell 3
Strong Sell 0
Total 25
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 20-Feb-25 14-Nov-24
Paid 10-Apr-25 09-Jan-25
Amount 16.00p 15.00p

Trades for 11-Apr-2025

Time Volume / Share Price
13:55 541 @ 1,284.18p
13:55 0 @ 1,283.50p
13:55 748 @ 1,284.00p
13:55 793 @ 1,284.00p
13:55 12 @ 1,284.00p

GSK Key Personnel

CEO Emma Walmsley

Top of Page